Invion Limited (ASX:IVX)
Invion Limited (ASX:IVX) is leading the development of a novel PhotoDynamic Therapy (PDT) for cancer. Invion’s novel photosensitiser (the agent used in PDT) is called IVX-PDT and is based on the PhotosoftTM Technology.
Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of the PhotosoftTM technology by licensor RMW Cho Group, which has funded and successfully commercialised a number of unique, advanced technologies.
Invion has an agreement with the Group to conduct the clinical development of the technology globally. RMW Cho Group provides funding for the research into and clinical trials of the PhotosoftTM Technology via a R&D services agreement with Invion. The provision of non-dilutive funding is part of a global development strategy for the technology.
In addition to this, Invion is collaborating with leading global medical research institutes – the Hudson Institute of Medical Research and the Peter MacCallum Cancer Centre – to progress the PhotosoftTM Technology.